Aldeyra Therapeutics (NASDAQ: ALDX) reported Q1 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39).

"We are pleased with our progress in the first quarter, as we continued to advance our product pipeline for the treatment of immunological diseases," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Our research collaboration with Johnson & Johnson Innovation to develop novel drug candidates for systemic inflammatory diseases, the initiation of late-stage clinical testing in dry eye disease and allergic conjunctivitis, and the poster presentations of our ocular inflammation programs, all highlight the promise of our platform across a number of product candidates and indications. We look forward to multiple milestones over the next year, including Phase 2b and Phase 3 clinical results in dry eye disease and allergic conjunctivitis, respectively."

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.